NEW YORK – Researchers have been hunting for ways to target alterations in KRAS ever since the mutated gene was first discovered in cancer in the early 1980s. Now, as drugmakers race to bring the first drugs targeting mutated KRAS protein to cancer patients, one scientist at MD Anderson Cancer Center is trying a different approach to get at this elusive target: exosomes.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.